These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9045459)

  • 21. [Antithrombin III in intensive therapy].
    Baudo F; Caimi TM; Decataldo F; Calori G
    Minerva Anestesiol; 1999; 65(1-2 Suppl 1):71-6. PubMed ID: 10206028
    [No Abstract]   [Full Text] [Related]  

  • 22. Is antithrombin III for sepsis-associated disseminated intravascular coagulation really ineffective?
    Iba T; Thachil J
    Intensive Care Med; 2016 Jul; 42(7):1193-4. PubMed ID: 27143022
    [No Abstract]   [Full Text] [Related]  

  • 23. Coagulation inhibitors in sepsis and disseminated intravascular coagulation.
    Lee WL; Downey GP
    Intensive Care Med; 2000 Nov; 26(11):1701-6. PubMed ID: 11193281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Introduction to the Margaux Conference on Critical Illness: activation of the coagulation system in critical illnesses.
    Dhainaut JF
    Crit Care Med; 2000 Sep; 28(9 Suppl):S1-3. PubMed ID: 11007188
    [No Abstract]   [Full Text] [Related]  

  • 25. [Substitution therapy using antithrombin III concentrate].
    Thaler E; Lechner K
    Dtsch Med Wochenschr; 1982 Jan; 107(4):147-9. PubMed ID: 7056170
    [No Abstract]   [Full Text] [Related]  

  • 26. [Therapy with antithrombin III in burned children--pilot study].
    Del Principe D; Pietrantoni R; Menichelli A; Siviero MC; Luzi F; Colucci C; Orsini D
    Haematologica; 1990; 75 Suppl 2():33-40. PubMed ID: 2387549
    [No Abstract]   [Full Text] [Related]  

  • 27. [The use of antithrombin III concentrates in disseminated intravascular coagulation].
    Aoki N; Matsuki K; Sakata Y
    Rinsho Ketsueki; 1982 Jun; 23(6):804-10. PubMed ID: 7176087
    [No Abstract]   [Full Text] [Related]  

  • 28. [Preliminary study for the evaluation of the feasibility of a multicenter clinical trial for the evaluation of the therapeutic efficacy of an antithrombin III concentration (Immuno) in the intravascular coagulation syndrome].
    Palareti G; Legnani C; Ludovici S; Maccaferri M
    Haematologica; 1990; 75 Suppl 2():21-32. PubMed ID: 2201605
    [No Abstract]   [Full Text] [Related]  

  • 29. Renal diseases, disseminated intravascular coagulation, and antithrombin III.
    Brandt P; Jespersen J
    Nephron; 1983; 34(3):203-4. PubMed ID: 6877453
    [No Abstract]   [Full Text] [Related]  

  • 30. Antithrombin III modulator of coagulation and inflammatory reaction.
    Gajek H
    Acta Anaesthesiol Scand Suppl; 1997; 111():221-2. PubMed ID: 9421022
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapy with antithrombin III concentrate].
    Vinazzer H
    Haematologica; 1990; 75 Suppl 2():14-20. PubMed ID: 2201604
    [No Abstract]   [Full Text] [Related]  

  • 32. Current management of disseminated intravascular coagulation.
    Wheeler A; Rubenstein EB
    Oncology (Williston Park); 1994 Sep; 8(9):69-73; discussion 73-6, 79. PubMed ID: 7993725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin.
    Kamikubo Y; Hamuro T; Matsuda J; Shinya N; Miyamoto S; Funatsu A; Kato H
    Thromb Haemost; 1996 Oct; 76(4):621-6. PubMed ID: 8903006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disseminated intravascular coagulation with multiple arterial thromboses responding to antithrombin-III concentrate infusion.
    Wisecarver JL; Haire WD
    Thromb Res; 1989 Jun; 54(6):709-17. PubMed ID: 2781511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The initial experience of antithrombin III in the management of neonates with necrotizing enterocolitis.
    St Peter SD; Little DC; Calkins CM; Holcomb GW; Snyder CL; Ostlie DJ
    J Pediatr Surg; 2007 Apr; 42(4):704-8. PubMed ID: 17448770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical trial of protease inhibitor in the treatment of fulminant hepatitis].
    Yasunaga M; Mori K; Yamashita S; Okita K
    Nihon Rinsho; 1991 Sep; 49(9):2120-4. PubMed ID: 1960877
    [No Abstract]   [Full Text] [Related]  

  • 37. Antithrombin III in patients admitted to intensive care units: a multicenter observational study.
    Messori A; Vacca F; Vaiani M; Trippoli S;
    Crit Care; 2002 Oct; 6(5):447-51. PubMed ID: 12398786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study.
    Aibiki M; Fukuoka N; Nishiyama T; Maekawa S; Shirakawa Y
    Shock; 2007 Aug; 28(2):141-7. PubMed ID: 17515857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antithrombin III and sepsis.
    Mammen EF
    Intensive Care Med; 1998 Jul; 24(7):649-50. PubMed ID: 9722032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.